Category: Series

It's time for ... Indicators of the Week! It is our show where we talk about fascinating numbers from the news. On today's episode, America's small GDP increase, a big assist from China's government to its lower income residents, and a high-grossing, centuries-old Monkey King.

Related Episodes:
How Red Lobster got cooked and other indicators
China's luxury liquor indicator

For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org.

Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

Peak 65 is here. More than 4 million Americans will turn 65 each year between 2024 and 2027, representing the largest retirement surge in history. Years ago, older Americans could count on Social Security. But today there is some uncertainty on the program's solvency in the next decade plus. Now, many are entering their golden years with financial insecurity. Today on the show, how did Social Security become a thing? And what could the safety net for the Peak 65 generation and beyond look like?

James Chappel's book: Golden Years: How Americans Invented and Reinvented Old AgeGolden Years: How Americans Invented and Reinvented Old Age

Related episodes:
Iceberg ahead for Social Security (Apple / Spotify)
What would it take to fix retirement? (Apple / Spotify)
Social Insecurity

For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org.

Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

A group of obscure yet powerful players in the prescription drug industry are under the microscope. On Tuesday, at a Senate hearing in D.C., the head of pharmaceutical giant Novo Nordisk blamed the health insurance industry and pharmacy benefit managers, or PBMs, for allegedly making products like the weight loss drug Ozempic way more expensive in the U.S. than it is in other countries. A few days before that, the Federal Trade Commission sued three of the country's largest PBMs for allegedly using unfair tactics to artificially inflate the price of insulin.

So what exactly are PBMs and how do they work? In an episode that aired two years ago, we explain how the answer involves secret deals and double agents.

Related episodes:
Who can and cannot get weight loss drugs (Apple / Spotify)
New drugs. Cheaper drugs. Why not both? (Apple / Spotify)

For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org.

Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy